Gennao Bio Announces Upcoming Presentation at the American Association for Cancer Research (AACR) Annual Meeting 2024

- Poster presentation to highlight the application of Gennao’s gene monoclonal antibody (GMAB) platform as an antibody-drug conjugate (ADC) for solid tumors -

HOPEWELL, N.J.--(BUSINESS WIRE)--Gennao Bio, a privately held genetic medicines company developing first-in-class, targeted nucleic acid therapeutics, today announced that an abstract reporting preclinical results of its non-viral, cell penetrating gene monoclonal antibody (GMAB) platform technology has been selected for poster presentation at the upcoming American Association for Cancer Research (AACR) Annual Meeting 2024, taking place April 5 – 10, 2024 in San Diego, CA. The poster presentation will showcase exploratory research conducted through Gennao’s ongoing collaboration with the laboratory of Peter M. Glazer, M.D., Ph.D., Chair of the Department of Therapeutic Radiology, Professor of Genetics and Robert E. Hunter Professor of Therapeutic Radiology at the Yale School of Medicine.  Specifically, the presentation will demonstrate the potential application of the GMAB platform as an antibody-drug conjugate (ADC) for the treatment of solid tumors.

The details of the poster presentation are as follows:

Abstract Number: 5801
Title: Targeted delivery of Exatecan to tumors via a novel cell-penetrating, anti-DNA antibody
Session Title: Cancer Treatment: New Technologies
Session Date and Time: Tuesday, April 9, 2024; 1:30 p.m. – 5:00 p.m. Pacific Daylight Time
Presenter: Zaira Ianniello, Ph.D., Yale School of Medicine
Location: Poster Section 22; Poster Number 10

About Gennao Bio

Gennao Bio is a genetic medicines company developing first-in-class targeted nucleic acid therapeutics utilizing its proprietary, non-viral gene monoclonal antibody (GMAB) platform technology. GMAB is an adaptive technology that uses a novel, cell-penetrating antibody to specifically deliver nucleic acid payloads to select cells while distinctly avoiding the endocytic pathway. This next-generation delivery platform is differentiated from traditional gene delivery systems, as it can rapidly and efficiently deliver multiple types of payloads for release in the cytoplasm and nucleus, allows for repeat dosing, and employs well-established antibody manufacturing processes. Gennao Bio is developing this delivery system with an initial focus on addressing significant unmet needs in skeletal muscle diseases and oncology.